<span>Chromosomal Aberration Assay: Unraveling the genetic puzzle to evaluate medical device safety through genetic toxicology</span>
April 15, 2024

Chromosomal Aberration Assay: Unraveling the genetic puzzle to evaluate medical device safety through genetic toxicology

Medical devices play a crucial role in the healthcare industry, and ensuring their safety is paramount to human health. Genotoxicity assessment, also known as genetox testing, is an essential aspect of medical device development. In the evolving landscape of medical devices, Labcorp’s Chromosomal Aberration Assay plays an important role in the assessment of genotoxic potential of these devices, evaluating their safety at a chromosomal level. Let’s explore the significance of this assay and how this powerful tool can assess potential risks associated with medical devices and human health.
Read more »
April 11, 2024

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , April 11, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024 , to
Read more »
<span>New Vivarium Wing in Münster</span>
April 8, 2024

New Vivarium Wing in Münster

Immuno-oncology. Biologics. Cell and gene therapies. This is the future of medicine. It’s more personalized, more complex and driving an increase in demand for highly technical nonclinical studies that require study models that most closely resemble the human body. Oftentimes, it’s nascent science that demands a new study that hasn’t even been invented yet.
Read more »